World Health Organization WHO: World Health Organization Coronavirus (COVID-19) Dashboard. https://covid19.who.int. Accessed 1 Aug 2023.

Davis HE, Assaf GS, McCorkell L, Wei H, Low RJ, Re’em Y, Redfield S, Austin JP, Akrami A. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021 Aug;38:101019. https://doi.org/10.1016/j.eclinm.2021.101019. Epub 2021 Jul 15. PMID: 34308300; PMCID: PMC8280690.

Chen C, Haupert SR, Zimmermann L, Shi X, Fritsche LG, Mukherjee B. Global prevalence of post-coronavirus disease 2019 (COVID-19) condition or long COVID: a meta-analysis and systematic review. J Infect Dis. 2022;226(9):1593–607. https://doi.org/10.1093/infdis/jiac136. PMID: 35429399; PMCID: PMC9047189.

Crook H, Raza S, Nowell J, Young M, Edison P. Long covid-mechanisms, risk factors, and management. BMJ. 2021 Jul 26;374:n1648. https://doi.org/10.1136/bmj.n1648. Erratum in: BMJ. 2021 Aug 3;374:n1944. PMID: 34312178.

• Lopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R, Rebolledo PA, Cuapio A, Villapol S. More than 50 Long-term effects of COVID-19: a systematic review and meta-analysis. medRxiv [Preprint]. 2021 Jan 30:2021.01.27.21250617. https://doi.org/10.1101/2021.01.27.21250617. Update in: Sci Rep. 2021 Aug 9;11(1):16144. PMID: 33532785; PMCID: PMC7852236. This is a comprehensive literature search and review of the documented side effects noted in Covid-19 infection and organized by body system. It is presented in a straightforward way and is very informative.

Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023 Mar;21(3):133-146. https://doi.org/10.1038/s41579-022-00846-2. Epub 2023 Jan 13. Erratum in: Nat Rev Microbiol. 2023 Jun;21(6):408. PMID: 36639608; PMCID: PMC9839201.

Wostyn P. COVID-19 and chronic fatigue syndrome: Is the worst yet to come? Med Hypotheses. 2021 Jan;146:110469. https://doi.org/10.1016/j.mehy.2020.110469. Epub 2021 Jan 2. PMID: 33401106; PMCID: PMC7836544.

Raveendran AV, et al. Long COVID: an overview. Diabetes & Metabolic Syndrome: Clinical Research and Reviews. 2021 May-June;15(3):869–75. PMID: 33892403

Article  CAS  Google Scholar 

Liu LD, Duricka DL. Stellate ganglion block reduces symptoms of long COVID: a case series. J Neuroimmunol. 2022;362: 577784.

Article  CAS  PubMed  Google Scholar 

Liu PP, Blet A, Smyth D, Li H. The science underlying Covid-19: implications for the cardiovascular system. Circulation. 2020;142:68–78.

Article  CAS  PubMed  Google Scholar 

Hamming I, Cooper ME, Haagmans BL, Hooper NM, Korstanje R, Osterhaus AD, Timens W, Turner AJ, Navis G, van Goor H. The emerging role of ace2 in physiology and disease. J Pathol. 2007;212:1–11.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Reynolds HR, Adhikari S, Pulgarin C, Troxel AB, Iturrate E, Johnson SB, Hausvater A, Newman JD, Berger JS, Bangalore S, Katz SD, Fishman GI, Kunichoff D, Chen Y, Ogedegbe G, Hochman JS. Renin-angiotensin-aldosterone system inhibitors and risk of Covid-19. N Engl J Med. 2020 Jun 18;382(25):2441-2448. https://doi.org/10.1056/NEJMoa2008975. Epub 2020 May 1. PMID: 32356628; PMCID: PMC7206932.

Chansrichavala P, Chantharaksri U, Sritara P, Chaiyaroj SC. Atorvastatin attenuates TLR4-mediated NF-kappaB activation in a MyD88-dependent pathway. Asian Pac J Allergy Immunol. 2009;27(1):49–57 (PMID: 19548630).

CAS  PubMed  Google Scholar 

Rios JL. Effects of triterpenes on the immune system. J Ethnopharmacol. 2010;128:1–14.

Article  CAS  PubMed  Google Scholar 

Boucas AP, Rheinheimer J, Lagopoulos J. Why severe COVID-19 patients are at greater risk of developing depression: a molecular perspective. Neuroscientist. 2022;28(1):11–9.

Article  CAS  PubMed  Google Scholar 

Iadecola C, Anrather J, Kamel H. Effects of COVID-19 on the nervous system. Cell. 2020;183(1):16-27.e1.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Low RN, Low RJ, Akrami A. A cytokine-based model for the pathophysiology of long COVID symptoms. SciLIT. (preprints).

Mukaetova-Ladinska EB, Kronenberg G, Raha-Chowdhury R. COVID-19 and neurocognitive disorders. Curr Opin Psychiatry. 2021;34(2):149–56.

Article  PubMed  Google Scholar 

Baig AM. Deleterious outcomes in Long-Hauler COVID-19: the effects of SARS-CoV-2 on the CNS in chronic COVID syndrome. ACS Chem Neurosci. 2020;11(24):4017–20.

Article  CAS  PubMed  Google Scholar 

Ostergaard L. SARS CoV-2 related microvascular damage and symptoms during and after COVID-19: consequences of capillary transit-time changes, tissue hypoxia and inflammation. Physiol Rep.Metabolic 2021;9(3): e14726.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Scoppettuolo P, Borrelli S, Naeije G. Neurological involvement in SARS-CoV-2 infection: a clinical systematic review. Brain Behav Immun Health. 2020;5: 100094.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen Y, Yang W, Chen F, et al. COVID-19 and cognitive impairment: neuroinvasive and blood-brain barrier dysfunction. J Neuroinflammation. 2022;19:222. https://doi.org/10.1186/s12974-022-02579-8.

Article  PubMed  PubMed Central  Google Scholar 

Qin Y, Wu J, Chen T, et al. Long-term microstructure and cerebral blood flow changes in patients recovered from COVID-19 without neurological manifestations. J Clin Invest. 2021;131(8): e147329.

Article  PubMed  PubMed Central  Google Scholar 

Lu Y, Li X, Geng D, et al. Cerebral micro-structural changes in COVID-19 patients – an MRI-based 3-month follow-up study. EClinicalMedicine. 2020;25: 100484.

Article  PubMed  PubMed Central  Google Scholar 

Weinstock LB, Brook JB, Walters AS, Goris A, Afrin LB, Molderings GJ. Mast cell activation symptoms are prevalent in Long-COVID. Int J Infect Dis. 2021;112:217–26.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Albornoz EA, Amarilla AA, Modhiran N, et al. SARS-CoV-2 drives NLRP3 inflammasome activation in human microglia through spike protein. Mol Psychiatry. 2022. https://doi.org/10.1038/s41380-022-01831-0.

Article  PubMed  Google Scholar 

Porzionato A, Emmi A, Barbon S, Boscolo-Berto R, Stecco C, Stocco E, Macchi V, De Caro R. Sympathetic activation: a potential link between comorbidities and COVID-19. FEBS J. 2020;287(17):3681–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tana C, Bentivegna E, Cho SJ, et al. Long COVID headache. J Headache Pain. 2022;23:93.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nigro E, Polito R, Alfieri A, et al. Molecular mechanisms involved in the positive effects of physical activity on coping with COVID-19. Eur J Appl Physiol. 2020;120:2569–82. https://doi.org/10.1007/s00421-020-04484-5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Disser NP, DeMicheli AJ, Schonk MM, Konnaris MA, Piacentini AN, Edon DL, Toresdahl BG, Rodeo SA, Casey EK, Mendias CL. Musculoskeletal consequences of Covid-19. J Bone Joint Surg Am. 2020;102:1197–204.

Article  PubMed  Google Scholar 

Wood E, Hall KH, Tate W. Role of mitochondria, oxidative stress and the response to antioxidants in myalgic encephalomyelitis/chronic fatigue syndrome: a possible approach to SARS-CoV-2 ‘long-haulers’? Chronic Dis Transl Med. 2020. https://doi.org/10.1016/j.cdtm.2020.11.002.

Barker-Davies RM, et al. The Stanford Hall consensus statement for post-COVID-19 rehabilitation. Br J Sports Med. 2020;54:949–59. https://doi.org/10.1136/bjsports-2020-102596.

Article  PubMed  Google Scholar 

Feigin G, Velasco Figueroa S, Englesakis MF, et al. Stellate ganglion block for non-pain indications: a scoping review. Pain Medicine. 2023;24:775–81.

Article  PubMed  Google Scholar 

Barizien N, Le Guen M, Russel S, et al. Clinical characterization of dysautonomia in long COVID-19 patients. Sci Rep. 2021;11:14042.

Article  CAS  PubMed  PubMed Central  Google Scholar